Trial drug did not improve scores in two MS studies
Key Takeaway
Elezanumab did not improve the main study score in either trial of people with relapsing or progressive MS.
What They Found
Researchers tested elezanumab at two doses against a placebo (a treatment with no active drug). Neither dose improved the main study score in people with relapsing MS. Neither dose improved that score in people with progressive MS. Serious health problems occurred at similar rates across treatment groups in both trials. Falls, urinary tract infections, and headaches were reported in both trials among people given elezanumab.
Who Should Care and Why
The trials included people with relapsing MS and people with progressive MS. Researchers tested whether adding elezanumab to their usual care improved a study score. People with relapsing MS took part in one trial. People with progressive MS took part in the other. Neither group showed improvement on the main study score.
Important Considerations
You should know these were randomized trials, meaning researchers assigned 331 people to elezanumab or a placebo by chance. You cannot tell from this abstract how the main study score relates to daily life. You also cannot tell whether rare or long-term harms might occur.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.